Latest Pharma Insights
Stock Watch: Pharma Reaches For Substitutes As Organic Growth Founders
Investors expect earnings season to be about growth. This quarter, big pharma’s focus on cost-cutting and M&A revealed how deep the organic growth problem runs. Meanwhile, one merger rumor exposed the fragility beneath AstraZeneca’s bullish targets.
Scrip - August 18, 2026
Investors expect earnings season to be about growth. This quarter, big pharma’s focus on cost-cutting and M&A revealed how deep the organic growth problem runs. Meanwhile, one merger rumor exposed the fragility beneath AstraZeneca’s bullish targets.
Scrip - August 18, 2026
GBMA Pushes For PBS Pricing Reform To Stave Off Australian Shortages
Australia’s generics and biosimilars body has called for PBS pricing, stockholding and regulatory reforms to make medicine supply more commercially sustainable and prevent shortages before they reach patients.
Generics Bulletin - August 18, 2026
Australia’s generics and biosimilars body has called for PBS pricing, stockholding and regulatory reforms to make medicine supply more commercially sustainable and prevent shortages before they reach patients.
Generics Bulletin - August 18, 2026
Cook Medical Phishing, Baylor Genetics Breach Deepen Medtech Cybersecurity Concerns
Cook Medical and Baylor Genetics are the latest in a string of 2026 medtech cyber incidents that also hit Stryker, Intuitive, Medtronic, iRhythm and Abbott.
Medtech Insight - August 18, 2026
Cook Medical and Baylor Genetics are the latest in a string of 2026 medtech cyber incidents that also hit Stryker, Intuitive, Medtronic, iRhythm and Abbott.
Medtech Insight - August 18, 2026
Insilico Medicine Launches Virtual Aging Cell Platform For Drug Discovery
Insilico's new platform combines AI, aging biology and virtual-cell modeling to support drug discovery.
Scrip - August 18, 2026
Insilico's new platform combines AI, aging biology and virtual-cell modeling to support drug discovery.
Scrip - August 18, 2026
Expectations Vs. Reality: Formycon Faces Muted Stelara Biosimilar Momentum
Formycon confirmed its full-year revenue guidance of €60m–€70m, leaning on expected growth from the underperforming ustekinumab and far-from-launch but promising pembrolizumab biosimilars.
Generics Bulletin - August 18, 2026
Formycon confirmed its full-year revenue guidance of €60m–€70m, leaning on expected growth from the underperforming ustekinumab and far-from-launch but promising pembrolizumab biosimilars.
Generics Bulletin - August 18, 2026
Leo Strengthens Late-Stage Pipeline With Dersimelagon Buy
The Denmark-headquartered firm has acquired the rights to dersimelagon from Japan’s Tanabe Pharma, a potential competitor in the protoporphyria space to Clinuvel Pharmaceutical’s Scenesse.
Scrip - August 18, 2026
The Denmark-headquartered firm has acquired the rights to dersimelagon from Japan’s Tanabe Pharma, a potential competitor in the protoporphyria space to Clinuvel Pharmaceutical’s Scenesse.
Scrip - August 18, 2026
Strategic Intent: The Rise Of Mid-Cap Dealmakers
In this episode of Strategic Intent, Scrip’s Jessica Merrill unpacks how biopharma’s small-to-mid-cap players are stepping up as serious acquirers, using M&A to extend growth beyond their first commercial successes.
In Vivo - August 18, 2026
In this episode of Strategic Intent, Scrip’s Jessica Merrill unpacks how biopharma’s small-to-mid-cap players are stepping up as serious acquirers, using M&A to extend growth beyond their first commercial successes.
In Vivo - August 18, 2026
Sumitomo Hit By Second Gotham Broadside Over CiRA Claims
Japanese company faces fresh attack from US investment group questioning its relationship with a high-profile cell therapy research center and Nobel Laureate in Japan.
Scrip - August 18, 2026
Japanese company faces fresh attack from US investment group questioning its relationship with a high-profile cell therapy research center and Nobel Laureate in Japan.
Scrip - August 18, 2026
US Cosmetics Industry Pushes Back on China’s Trade-Busting GMP Certificate Requirement
As US regulators develop a trade board to manage bilateral trade with China, the US cosmetics industry is looking for solutions to cosmetics regulatory differences between the countries.
HBW Insight - August 18, 2026
As US regulators develop a trade board to manage bilateral trade with China, the US cosmetics industry is looking for solutions to cosmetics regulatory differences between the countries.
HBW Insight - August 18, 2026
Stock Watch: Pharma Reaches For Substitutes As Organic Growth Founders
Investors expect earnings season to be about growth. This quarter, big pharma’s focus on cost-cutting and M&A revealed how deep the organic growth problem runs. Meanwhile, one merger rumor exposed the fragility beneath AstraZeneca’s bullish targets.
Scrip - August 18, 2026
Investors expect earnings season to be about growth. This quarter, big pharma’s focus on cost-cutting and M&A revealed how deep the organic growth problem runs. Meanwhile, one merger rumor exposed the fragility beneath AstraZeneca’s bullish targets.
Scrip - August 18, 2026
Insilico Medicine Launches Virtual Aging Cell Platform For Drug Discovery
Insilico's new platform combines AI, aging biology and virtual-cell modeling to support drug discovery.
Scrip - August 18, 2026
Insilico's new platform combines AI, aging biology and virtual-cell modeling to support drug discovery.
Scrip - August 18, 2026
Leo Strengthens Late-Stage Pipeline With Dersimelagon Buy
The Denmark-headquartered firm has acquired the rights to dersimelagon from Japan’s Tanabe Pharma, a potential competitor in the protoporphyria space to Clinuvel Pharmaceutical’s Scenesse.
Scrip - August 18, 2026
The Denmark-headquartered firm has acquired the rights to dersimelagon from Japan’s Tanabe Pharma, a potential competitor in the protoporphyria space to Clinuvel Pharmaceutical’s Scenesse.
Scrip - August 18, 2026
Sumitomo Hit By Second Gotham Broadside Over CiRA Claims
Japanese company faces fresh attack from US investment group questioning its relationship with a high-profile cell therapy research center and Nobel Laureate in Japan.
Scrip - August 18, 2026
Japanese company faces fresh attack from US investment group questioning its relationship with a high-profile cell therapy research center and Nobel Laureate in Japan.
Scrip - August 18, 2026
Cook Medical Phishing, Baylor Genetics Breach Deepen Medtech Cybersecurity Concerns
Cook Medical and Baylor Genetics are the latest in a string of 2026 medtech cyber incidents that also hit Stryker, Intuitive, Medtronic, iRhythm and Abbott.
Medtech Insight - August 18, 2026
Cook Medical and Baylor Genetics are the latest in a string of 2026 medtech cyber incidents that also hit Stryker, Intuitive, Medtronic, iRhythm and Abbott.
Medtech Insight - August 18, 2026
US Cosmetics Industry Pushes Back on China’s Trade-Busting GMP Certificate Requirement
As US regulators develop a trade board to manage bilateral trade with China, the US cosmetics industry is looking for solutions to cosmetics regulatory differences between the countries.
HBW Insight - August 18, 2026
As US regulators develop a trade board to manage bilateral trade with China, the US cosmetics industry is looking for solutions to cosmetics regulatory differences between the countries.
HBW Insight - August 18, 2026
GBMA Pushes For PBS Pricing Reform To Stave Off Australian Shortages
Australia’s generics and biosimilars body has called for PBS pricing, stockholding and regulatory reforms to make medicine supply more commercially sustainable and prevent shortages before they reach patients.
Generics Bulletin - August 18, 2026
Australia’s generics and biosimilars body has called for PBS pricing, stockholding and regulatory reforms to make medicine supply more commercially sustainable and prevent shortages before they reach patients.
Generics Bulletin - August 18, 2026
Expectations Vs. Reality: Formycon Faces Muted Stelara Biosimilar Momentum
Formycon confirmed its full-year revenue guidance of €60m–€70m, leaning on expected growth from the underperforming ustekinumab and far-from-launch but promising pembrolizumab biosimilars.
Generics Bulletin - August 18, 2026
Formycon confirmed its full-year revenue guidance of €60m–€70m, leaning on expected growth from the underperforming ustekinumab and far-from-launch but promising pembrolizumab biosimilars.
Generics Bulletin - August 18, 2026
Strategic Intent: The Rise Of Mid-Cap Dealmakers
In this episode of Strategic Intent, Scrip’s Jessica Merrill unpacks how biopharma’s small-to-mid-cap players are stepping up as serious acquirers, using M&A to extend growth beyond their first commercial successes.
In Vivo - August 18, 2026
In this episode of Strategic Intent, Scrip’s Jessica Merrill unpacks how biopharma’s small-to-mid-cap players are stepping up as serious acquirers, using M&A to extend growth beyond their first commercial successes.
In Vivo - August 18, 2026